Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Early Stage Triple Negative ER Low Breast Cancer 1

Interventions

Specimen Handling 655 pembrolizumab 608 Magnetic Resonance Spectroscopy 561 Carboplatin 449 Cisplatin 398 Cyclophosphamide 396 Biopsy 380 Nivolumab 325 Paclitaxel 323 Gemcitabine 317 Radiotherapy 298 Bevacizumab 248 Dexamethasone 223 fludarabine 215 Docetaxel 202 durvalumab 195 Oxaliplatin 189 venetoclax 186 atezolizumab 183 Fluorouracil 177 Rituximab 176 Pemetrexed 173 Capecitabine 170 Radiation 168 Doxorubicin 166 Radiosurgery 161 Ipilimumab 147 Etoposide 142 Leucovorin 140 Lenalidomide 139

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interleukin 1 Receptor Antagonist Protein × 90 days × Clear all

NCT06710197 2026-03-05

OZM-034

University Health Network, Toronto

Phase 2 Withdrawn

Early Stage Triple Negative ER Low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡